The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of the MARS study on the management of antiangiogenics’ renovascular safety in ovarian cancer.
Vincent Launay-Vacher
No relevant relationships to disclose
Nicolas Janus
Consultant or Advisory Role - Pfizer
Honoraria - Fresenius ; Roche
Frédéric Selle
No relevant relationships to disclose
Francois Goldwasser
Consultant or Advisory Role - Roche
Honoraria - Roche
Olivier Mir
Consultant or Advisory Role - Pfizer; Roche
Honoraria - Pfizer
Jean-Philippe Spano
No relevant relationships to disclose
Jean Christophe Thery
No relevant relationships to disclose
Philippe Beuzeboc
No relevant relationships to disclose
Jean-Baptiste Rey
No relevant relationships to disclose
Christelle Jouannaud
No relevant relationships to disclose
Jean F. Morere
No relevant relationships to disclose
Stephane Oudard
No relevant relationships to disclose
Joseph Gligorov
No relevant relationships to disclose
Michel Azizi
No relevant relationships to disclose
Richard Dorent
No relevant relationships to disclose
Gilbert Deray
No relevant relationships to disclose
Isabelle Laure Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche
Research Funding - PharmaMar; Roche
Florian Scotte
No relevant relationships to disclose